[(5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: [(5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
• 化学式: C₁₇H₂₃NO₃
• 分子量: 289.4
• InChiKey: RKUNBYITZUJHSG-JYLOXXHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Compositions and Methods for Treating Social Anxiety
  申请人：Holly Benjamin D.

  公开号：US20110218215A1

  公开（公告）日：2011-09-08

  The disclosure provides a pharmaceutical composition for treating social anxiety, performance anxiety, and social phobia comprising a therapeutic amount for die treatment of a patient of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound. The β-adrenergic receptor antagonist may be the lipophilic β-blocker propranolol HCl, the anti-diarrheal compound may be the opioid diphenoxylate HCl, and the optional anticholinergic compound may be atropine sulfate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating social anxiety, performance anxiety, and social phobia in a patient is also provided, comprising administering a composition of the disclosure to a patient in need of such treatment. The composition administered in the present method comprises a therapeutic amount of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound.

  本公开提供了一种用于治疗社交焦虑、表演焦虑和社交恐惧症的药物组合物，包括治疗量的β-肾上腺素受体拮抗剂、抗腹泻化合物和可选的抗胆碱能化合物。β-肾上腺素受体拮抗剂可以是亲脂性β受体阻滞剂丙酸异丙苯基胺盐酸盐，抗腹泻化合物可以是阿片类地芬诺酯盐酸盐，可选的抗胆碱能化合物可以是硫酸阿托品。用于治疗表演焦虑和社交恐惧症的组合物还可以包括药学上可接受的载体。本公开还提供了一种预防或治疗患者社交焦虑、表演焦虑和社交恐惧症的方法，包括向需要此类治疗的患者给予本公开所述的组合物。本方法中给予的组合物包括治疗量的β-肾上腺素受体拮抗剂、抗腹泻化合物和可选的抗胆碱能化合物。
• SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY
  申请人：The Governmen of the United States of America, as represented by Secretary, Department of Health and

  公开号：US20140378501A1

  公开（公告）日：2014-12-25

  Provided are methods and compositions for the treatment of depression and anxiety. The compositions contain scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler containing scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
• INHALABLE MEDICAMENT
  申请人：Teva Branded Pharmaceutical Products R&D, Inc.

  公开号：US20150190510A1

  公开（公告）日：2015-07-09

  The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.
• AN INHALABLE MEDICAMENT
  申请人：Teva Branded Pharmaceutical Products R&D, Inc.

  公开号：US20160250197A1

  公开（公告）日：2016-09-01

  Accordingly, the present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.
• US8859585B2
  申请人：——

  公开号：US8859585B2

  公开（公告）日：2014-10-14